Growth kinetics study and microarray analysis on MCF-7 cells treated with recombinant bromelain /
Cancer has long been viewed as one of the leading causes of death. Different types of cancer therapeutics have been used to treat cancer. However, most of them give negative side effect to human health. Therefore, this researchis purposedto study the potential of recombinant bromelain as anti-cancer...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
Kuala Lumpur :
Kulliyyah of Engineering, International Islamic University Malaysia,
2013
|
| Subjects: | |
| Online Access: | Click here to view 1st 24 pages of the thesis. Members can view fulltext at the specified PCs in the library. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Cancer has long been viewed as one of the leading causes of death. Different types of cancer therapeutics have been used to treat cancer. However, most of them give negative side effect to human health. Therefore, this researchis purposedto study the potential of recombinant bromelain as anti-cancer agent. This was achieved by studying the growth kinetics behavior of MCF-7 breast cancer cells after treated with bromelain and recombinant bromelain and analyzing the changes through affected cancer related genes by microarray analysis. The effects of bromelain and recombinant bromelain were observed by anti-proliferative test using SRB assay. The assay was used to indicate the bromelain and recombinant bromelain half maximal inhibitory concentration (ICso). Bromelain and recombinant bromelain gave a strong effect towards decreasing the cell viability of MCF-7 cells with ICso value of 5.125 μg/mL and 6.25μg/mL, respectively, compared to taxol with ICso value of 0.063 μg/mL.The effects of bromelain and recombinant bromelain were further scrutinized by developing a growth kinetics model associated with microarray analysis to forecast it ability in eradicating the growth of cancer cells.The present results indicate that bromelain and recombinant bromelain proved its anti-proliferative activity when they reduced the number of cells generations from 3.92 to 2.81 generations for bromelain and 2.86 generations for recombinant bromelain, respectively. Observation under microscope on bromelain-treated MCF-7 demonstrated detachment experience. While taxol reduced the number of cells generations ofMCF-7 from 3.92 to 3.12generations. The inhibition activities obviously can be verified when the growth rate was decreased dynamically from 0.009 h61 to 0.0059 hc:>1for bromelainand from 0.009 h61to 0.0063 h61for recombinant bromelain, respectively. The results of the microarray analysis revealed several genes differentially expressed by MCF-7 cells following 1 hour and 48 hours of recombinant bromelain treatment. The affected genes were BTG 1, HIST1H2BN, PURA, AZIN and MAP3K7IP2, involved in diurnally regulated genes pathway related to cancer progression. Moreover, RMBSI and TBPL1ISLC2AI2 involved in Hs-lymphocyte-TarBase pathway and AKT/PKB involved in ERBB signaling pathway, and lastly, kinesin-associated protein 3 involved in Kinesin pathway. Finally, Real-Time (Rn-qPCR analysis was used as binary validation of the targeted genes affected by recombinant bromelain. In conclusion, recombinant bromelain can be one of the promising anti-cancer agents which much safer and effective. |
|---|---|
| Physical Description: | xiv, 182 leaves : ill. ; 30cm. |
| Bibliography: | Includes bibliographical references (leaves 125-140). |